Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sarah Jo, Stephens"'
Autor:
Moiez Ali, Erin Kaltenbrun, Grace R. Anderson, Sarah Jo Stephens, Sabrina Arena, Alberto Bardelli, Christopher M. Counter, Kris C. Wood
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
KRAS mutations drive resistance to diverse targeted therapies. In this study, the authors show that the rare codons of KRAS, yielding low oncogene expression, can be overcome to drive resistance to anti-EGFR therapy in CRC through upregulation of glo
Externí odkaz:
https://doaj.org/article/758523a625184d568c02dd0233d59ad9
Publikováno v:
Brachytherapy. 21:S35-S36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::878fc94fb2fb910e6d6d95656281e5f1
https://doi.org/10.1016/j.brachy.2022.09.039
https://doi.org/10.1016/j.brachy.2022.09.039
Autor:
Jessica Lee, Sarah Jo Stephens, Zheng Chang, Sheridan Meltsner, Oana Craciunescu, Junzo Chino
Publikováno v:
Brachytherapy. 21:S52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a65fc691c89717f0c1948fb59825114
https://doi.org/10.1016/j.brachy.2022.09.069
https://doi.org/10.1016/j.brachy.2022.09.069
Autor:
Devon J, Godfrey, Sarah Jo, Stephens, Daniele, Marin, Michael J, Moravan, Joseph K, Salama, Manisha, Palta
Publikováno v:
J Radiosurg SBRT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a9ece5e6d5f6e97d5d8318cf773f315
https://pubmed.ncbi.nlm.nih.gov/33898090
https://pubmed.ncbi.nlm.nih.gov/33898090
Publikováno v:
Practical Guides in Radiation Oncology ISBN: 9783319648996
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc98de302ec3f907d29fddf2c6865732
https://doi.org/10.1007/978-3-319-64900-9_11
https://doi.org/10.1007/978-3-319-64900-9_11
Autor:
Fumiko, Chino, Sarah Jo, Stephens, Steve S, Choi, Daniele, Marin, Charles Y, Kim, Michael A, Morse, Devon J, Godfrey, Brian G, Czito, Christopher G, Willett, Manisha, Palta
Publikováno v:
Cancer. 124(17)
Hepatocellular carcinoma (HCC) is increasing in incidence and mortality. Although the prognosis remains poor, long-term survival has improved from 3% in 1970 to an 18% 5-year survival rate today. This is likely because of the introduction of well tol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::704a6086038eeb76852ab3c086a3ac87
https://pubmed.ncbi.nlm.nih.gov/29645076
https://pubmed.ncbi.nlm.nih.gov/29645076